 Anip Bansal
Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Failure, Chronic | 4 | 2014 | 546 | 0.930 |
Why?
| | Renal Dialysis | 4 | 2014 | 423 | 0.790 |
Why?
| | Acute Kidney Injury | 6 | 2025 | 790 | 0.610 |
Why?
| | Ferritins | 2 | 2014 | 58 | 0.560 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2014 | 15 | 0.450 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 59 | 0.430 |
Why?
| | Iron | 1 | 2014 | 281 | 0.390 |
Why?
| | Bone Diseases, Metabolic | 1 | 2012 | 57 | 0.380 |
Why?
| | Hospital Mortality | 5 | 2021 | 846 | 0.350 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1021 | 0.270 |
Why?
| | Calcium | 1 | 2012 | 1212 | 0.260 |
Why?
| | gamma-Glutamyl Hydrolase | 1 | 2025 | 3 | 0.240 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2025 | 91 | 0.230 |
Why?
| | Intensive Care Units | 5 | 2021 | 736 | 0.230 |
Why?
| | Methotrexate | 1 | 2025 | 248 | 0.220 |
Why?
| | Inappropriate ADH Syndrome | 1 | 2023 | 8 | 0.210 |
Why?
| | Hyponatremia | 1 | 2023 | 39 | 0.200 |
Why?
| | Cisplatin | 1 | 2024 | 299 | 0.190 |
Why?
| | Running | 1 | 2023 | 223 | 0.170 |
Why?
| | Critical Illness | 3 | 2021 | 757 | 0.170 |
Why?
| | Renal Replacement Therapy | 1 | 2020 | 87 | 0.170 |
Why?
| | Dialysis Solutions | 1 | 2019 | 22 | 0.160 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 64 | 0.150 |
Why?
| | Middle Aged | 12 | 2025 | 31087 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 248 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 566 | 0.140 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 282 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 313 | 0.140 |
Why?
| | Heart Arrest | 1 | 2020 | 320 | 0.130 |
Why?
| | Pyrazoles | 1 | 2019 | 404 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 459 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 339 | 0.120 |
Why?
| | Critical Care | 1 | 2020 | 551 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 333 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 758 | 0.120 |
Why?
| | Pericardiocentesis | 1 | 2014 | 10 | 0.110 |
Why?
| | Colchicine | 1 | 2014 | 24 | 0.110 |
Why?
| | Oliguria | 1 | 2014 | 2 | 0.110 |
Why?
| | Hematinics | 1 | 2014 | 20 | 0.110 |
Why?
| | Pericardial Effusion | 1 | 2014 | 21 | 0.110 |
Why?
| | Intra-Abdominal Hypertension | 1 | 2014 | 6 | 0.110 |
Why?
| | Cohort Studies | 5 | 2024 | 5408 | 0.110 |
Why?
| | Asymptomatic Diseases | 1 | 2014 | 84 | 0.110 |
Why?
| | Administration, Intravenous | 1 | 2014 | 141 | 0.110 |
Why?
| | Hypotension | 1 | 2014 | 116 | 0.100 |
Why?
| | Hemodialysis Solutions | 1 | 2012 | 3 | 0.100 |
Why?
| | Aged | 7 | 2025 | 22032 | 0.100 |
Why?
| | Bacterial Infections | 1 | 2014 | 235 | 0.100 |
Why?
| | Humans | 17 | 2025 | 129248 | 0.100 |
Why?
| | Parathyroid Hormone | 1 | 2012 | 106 | 0.100 |
Why?
| | Glomerulonephritis | 1 | 2012 | 46 | 0.100 |
Why?
| | Quality Improvement | 1 | 2019 | 1095 | 0.090 |
Why?
| | Up-Regulation | 1 | 2014 | 839 | 0.090 |
Why?
| | Complement C3 | 1 | 2012 | 208 | 0.090 |
Why?
| | Aluminum | 1 | 2011 | 38 | 0.090 |
Why?
| | Calcinosis | 1 | 2012 | 231 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2008 | 0.080 |
Why?
| | Female | 9 | 2025 | 68543 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2024 | 14455 | 0.080 |
Why?
| | Male | 10 | 2025 | 63501 | 0.080 |
Why?
| | Adult | 8 | 2025 | 35495 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2012 | 504 | 0.080 |
Why?
| | Biomarkers | 2 | 2014 | 3966 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7055 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2021 | 10199 | 0.060 |
Why?
| | Neutropenia | 1 | 2025 | 136 | 0.060 |
Why?
| | Risk Factors | 3 | 2024 | 9745 | 0.050 |
Why?
| | Time Factors | 1 | 2014 | 6543 | 0.050 |
Why?
| | Diuretics | 1 | 2023 | 75 | 0.050 |
Why?
| | Vasopressins | 1 | 2023 | 64 | 0.050 |
Why?
| | Risk Assessment | 2 | 2024 | 3233 | 0.050 |
Why?
| | Pandemics | 2 | 2020 | 1482 | 0.050 |
Why?
| | Creatinine | 1 | 2024 | 491 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1304 | 0.050 |
Why?
| | Hospitalization | 2 | 2021 | 2052 | 0.040 |
Why?
| | Prone Position | 1 | 2021 | 30 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2021 | 37 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2021 | 44 | 0.040 |
Why?
| | Patient Positioning | 1 | 2021 | 52 | 0.040 |
Why?
| | Early Medical Intervention | 1 | 2021 | 57 | 0.040 |
Why?
| | United States | 3 | 2020 | 13828 | 0.040 |
Why?
| | Hospitals, University | 1 | 2019 | 179 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 307 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1197 | 0.040 |
Why?
| | Piperidines | 1 | 2019 | 198 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 768 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 522 | 0.030 |
Why?
| | Adenine | 1 | 2019 | 256 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 613 | 0.030 |
Why?
| | Anticoagulants | 1 | 2021 | 636 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 1869 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1984 | 0.030 |
Why?
| | Young Adult | 2 | 2021 | 12388 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2636 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 3140 | 0.030 |
Why?
| | Glomerulonephritis, Membranous | 1 | 2012 | 2 | 0.030 |
Why?
| | Adolescent | 2 | 2021 | 20303 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4406 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 978 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1430 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2737 | 0.010 |
Why?
|
|
Bansal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|